{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-119270","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.964871+00:00","generated_at":"2026-05-30T07:38:48.960436+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK appoints former HHS ASPR Robert Kadlec to board","bullets":["Dr. Robert Kadlec elected Class II director effective Oct. 30, 2024; term expires at 2026 annual meeting.","Previously served as HHS Assistant Secretary for Preparedness and Response and co-conceived Operation Warp Speed.","Will serve on Corporate Governance and Nominating Committee; granted option for 41,745 shares vesting over 3 years.","Expertise in biodefense and pandemic preparedness aligns with MiNK's iNKT cell therapy focus on ARDS and infectious diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-119270","json":"https://secwatch.observer/filing/0000950170-24-119270.json","markdown":"https://secwatch.observer/filing/0000950170-24-119270.md","text":"https://secwatch.observer/filing/0000950170-24-119270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024119270/0000950170-24-119270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024119270/inkt-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:38:48.960436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b8f1cd6db","claim":"Robert Kadlec was elected as Director at MiNK Therapeutics, Inc..","evidence_excerpt":"On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., (\"MiNK\") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024119270/0000950170-24-119270-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}